Parasol Med Tech, a Chicago-based medical device company, today announced that it has closed an oversubscribed $2.75 million pre-seed funding round. The round included participation from Harper Court Ventures, UChicago Medicine Ventures, a venture investment vehicle of the University of Chicago Medical Center, and Cardiovascular Innovation Ventures, the venture arm […]
Coronary/Structural Heart
Biograph Completes First U.S. Study with Caristo Diagnostics’ AI-Powered Coronary Inflammation Detection, Finding Risk in Over 42% of Asymptomatic Patients
SAN MATEO, Calif. & NEW YORK–(BUSINESS WIRE)–Biograph study shows AI imaging detected coronary inflammation in 43% of asymptomatic adults, which standard blood tests failed to identify.
Orchestra BioMed to Host R&D Day Featuring Clinical Insights and Development Plans for AVIM Therapy and Virtue® SAB
Company leadership, leading cardiologists and trial investigators to discuss unmet patient needs, BACKBEAT and Virtue pivotal trials, and upcoming milestones; in person in New York City and via live webcastNEW HOPE, Pa., Oct. 22, 2026 (GLOBE NEWSWIRE) — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced it will host an R&D Day on November 12th, 2026, at 3:00pm ET in New York City. The event will also be available via live webcast. Orchestra BioMed leadership will be joined by key leading cardiologists to discuss the clinical and treatment burden associated with uncontrolled hypertension in pacemaker-indicated patients and restenosis in coronary stent interventions, as well as the potential for AVIM Therapy and Virtue SAB to address these unmet needs. The program will also highlight key upcoming clinical milestones and explore the commercial potential of AVIM Therapy and Virtue SAB. R&D Day Agenda 3:00 PM | Opening Remarks Led by David Hochman, Chairman and Chief Executive Officer 3:10 PM | AVIM Therapy, BACKBEAT Pivotal Trial & Medtronic Strategic CollaborationLed by David Hochman & Avi Fischer, MD, Senior Vice President, Medical Affairs & Innovation Physician Speakers: Vivek Reddy, MD, Executive Chairman of the BACKBEAT Trial Steering Committee, Director of Cardiac Arrhythmia Services, Mount Sinai Hospital and the Mount Sinai Health SystemMarat Fudim, MD, Associate Professor of Cardiology, Advanced Heart Failure, Duke University Medical Center 4:20 PM | Virtue SAB & Virtue Pivotal Trial Led by Darren Sherman, President & Chief Operating OfficerPhysician Speakers: Dean Kereiakes, MD, Virtue Trial Co-PI, Chairman of The Christ Hospital Heart and Vascular Institute, The Christ Hospital Health NetworkAllen Jeremias, MD, Virtue Trial Co-PI, Director of the Cardiac Catheterization Laboratory at St. Francis Hospital & Heart Center, New York and an Executive Director for Optimizing PCI 5:15 PM | Q&A Closing Remarks Moderated by David Hochman and Darren Sherman Registration and Webcast Information The R&D Day will be held in person in New York City and streamed via live webcast, and available for replay following the event. In-person attendance: Please register here. Space is limited, and the Company may not be able to accommodate all requests. In-person registrations are subject to written confirmation, and venue and event details will be provided upon confirmation.Live webcast: Please register here to access the live webcast. A replay will be available on the Investors section of Orchestra BioMed’s website following the event. About Orchestra BioMed Orchestra BioMed is a biomedical innovation company accelerating high-impact technologies to patients through strategic collaborations with market-leading global medical device companies. The Company’s two flagship product candidates – Atrioventricular Interval Modulation (AVIM) Therapy and Virtue® Sirolimus AngioInfusion™ Balloon (Virtue SAB) – are currently undergoing pivotal clinical trials for their lead indications, each representing multi-billion-dollar annual global market opportunities. The BACKBEAT Global Pivotal Trial evaluating AVIM Therapy has completed enrollment. AVIM Therapy is a bioelectronic treatment for hypertension, the leading risk factor for death worldwide, and is designed to be delivered by a pacemaker and achieve immediate, substantial and sustained reductions in blood pressure in patients with hypertensive heart disease. The Company has a strategic collaboration with Medtronic (NYSE: MDT), one of the largest medical device companies in the world and the global leader in cardiac pacing therapies, for the development and commercialization of AVIM Therapy for the treatment of uncontrolled hypertension in pacemaker-indicated patients. AVIM Therapy has two FDA Breakthrough Device Designations. Virtue SAB is a first-of-its-kind, non-coated drug delivery Angioinfusion balloon system designed to infuse a large liquid dose of proprietary extended-release formulation of sirolimus, SirolimusEFR™, for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. Virtue SAB has been granted Breakthrough Device Designation by the FDA for the treatment of coronary in-stent restenosis, coronary small vessel disease and below-the-knee peripheral artery disease. The Virtue Pivotal Trial evaluating Virtue SAB for the treatment of coronary in-stent restenosis is currently enrolling patients. For further information about Orchestra BioMed, please visit www.orchestrabiomed.com, and follow us on LinkedIn. Investor Contact:Silas NewcombOrchestra BioMedsnewcomb@orchestrabiomed.com Media Contact:Nina PremuticoOrchestra BioMednpremutico@orchestrabiomed.com
Teleflex Announces FDA Breakthrough Device Designation for Freesolve™ Resorbable Magnesium Scaffold
WAYNE, Pa.–(BUSINESS WIRE)–Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation (BDD) for its Freesolve™ Resorbable Magnesium Scaffold (RMS) for percutaneous coronary intervention (PCI). To qualify for a BDD, device technology must address an unmet clinical need and show that it has the potential to provide for more effective treatment of life-threateni
FDA Approval of Edwards Lifesciences’ PASCAL Precision System Opens New Treatment Pathway for Patients With Tricuspid Valve Disease
IRVINE, Calif.–(BUSINESS WIRE)–Edwards Lifesciences Corporation (NYSE: EW) today announced that the U.S. Food and Drug Administration (FDA) has approved its PASCAL Precision system for tricuspid valve repair. The system is indicated for improving quality of life and functional status in patients with symptomatic severe tricuspid regurgitation (TR) despite optimal medical […]
egnite 2026 Benchmark Report: Four-Class GDMT Prescribing in Systolic Heart Failure More Than Doubles, Yet Four in Five Patients Are Not Prescribed Full Guideline Therapy
Real-world data from 47 U.S. health systems shows three-year survival of 76% among systolic heart failure patients prescribed four GDMT classes, versus 52% among those prescribed none ALISO VIEJO, Calif., Oct. 21, 2026 /PRNewswire/ — egnite, Inc., a technology company advancing…
Elucid Announces FDA Clearance of FFR-IQ™ and Commercial Availability of the Most Accurate¹ FFR-CT Software
BOSTON–(BUSINESS WIRE)– #510k–Elucid has received FDA 510(k) clearance of FFR-IQ™, its software for noninvasive estimation of fractional flow reserve from coronary CT angiography.
Philips highlights Integrated Diagnostics’ role in the future of cardiovascular informatics following MediReport acquisition
Philips cardiology informatics at TCT
Philips cardiology informatics at TCT
October 20, 2026 Advanced reporting and workflow capabilities developed by MediReport are expected to complement Philips’ cardiovascular informatics portfolio and support its evolution toward a more connected, AI-enabled and cloud-ready cardiovascular experience. Amsterdam, the Netherlands – October 20, 2026 – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today highlighted how advanced reporting and workflow capabilities developed by MediReport are expected to complement its cardiovascular informatics portfolio and support its broader Integrated Diagnostics vision ahead of Transcatheter Cardiovascular Therapeutics (TCT) 2026. Philips brings together expertise in diagnostic and interventional cardiology, image-guided therapy and informatics to support cardiovascular care, from diagnosis through intervention and follow-up. As part of its presence at TCT, Philips will showcase innovations that support clinical confidence, streamline workflows and make meaningful information easier to access, while engaging with customers and clinical leaders on opportunities to better connect diagnostic and interventional care. Cardiovascular teams often work across separate imaging, hemodynamic, documentation and reporting systems. This can require repeated data entry and delay access to the complete clinical information needed for procedure reporting, coding and follow-up. In Philips’ Future Health Index 2025: Cardiology Snapshot, 79% of cardiac care professionals surveyed reported losing clinical time because patient data was incomplete or inaccessible. Almost half of this group reported losing more than 45 minutes per shift [1]. These findings underline the need to make clinical information easier to capture, access and reuse across the care pathway. Following the acquisition of MediReport, Philips expects to strengthen its cardiovascular informatics capabilities. MediReport 360 supports structured cardiovascular documentation and real-time reporting at the point of care, with guided workflows before, during and after procedures. It enables health systems to capture clinical information once and reuse it across physician and nursing reports, coding, registries, analytics, charge capture and follow-up. MediReport’s technologies support cloud and on-premises deployment, with vendor-neutral interfaces to imaging systems, hemodynamic systems and hospital IT. This expected enhancement would build on Philips’ existing cardiology informatics portfolio, including Cardiovascular Workspace for image and information management, with cloud deployment available in North America; Ultrasound Workspace for ultrasound review, analysis and reporting; and interventional solutions supporting cath-lab information management and hemodynamic workflows. “Clinicians need technology that fits the way they work and gives them more time for patient care”, said Madhuri Sebastian, Business Unit Leader Imaging Informatics at Philips. “The capabilities developed by MediReport complement Philips’ strengths in cardiovascular imaging, hemodynamics and enterprise informatics. Together, they are expected to simplify how information moves across cardiac care, enabling a more connected experience for care teams. This would also support Philips’ longer-term direction towards cloud-ready, AI-enabled cardiovascular and integrated diagnostics workflows.” Visit Philips at TCT 2026 to explore innovations in imaging, physiology, procedural guidance and cardiovascular informatics that help care teams access meaningful information and simplify reporting and workflows. [1] Philips Future Health Index 2025: Cardiology Snapshot — Building trust in AI for cardiac care. For further information, please contact: Name Jayme ManiatisPhilips Global External RelationsTel.: +16178948368E-mail: name.here@philips.com About Royal Philips Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.Headquartered in the Netherlands, the company is a leader in image-guided therapy, diagnostic imaging, ultrasound, monitoring, enterprise informatics and personal health. Philips generated 2025 sales of approximately EUR 18 billion and employs approximately 63,700 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.
Attachment
Philips cardiology informatics at TCT
Johnson and Johnson Launches Next-Generation Shockwave™ C2 Aero Fly Coronary IVL Catheter, Cutting IVL Treatment Time in Half
SANTA CLARA, Calif.–(BUSINESS WIRE)–Next-generation IVL catheter delivers pulses at 2 Hz, improving efficiency in calcium modification treatment of coronary artery disease.
Anteris Advances Global PARADIGM Trial Expansion with German Regulatory Clearance
MINNEAPOLIS and BRISBANE, Australia, Oct. 19, 2026 (GLOBE NEWSWIRE) — Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) announced today that it has received full regulatory clearance from the German Federal Institute for Drugs and Medical Devices (BfArM) for the DurAVR® Transcatheter Heart Valve (THV) global pivotal trial for patients with severe calcific aortic stenosis (the “PARADIGM Trial”). This clearance enables Anteris to initiate patient recruitment at leading German centers and represents an important step in expanding the PARADIGM Trial’s European footprint. Germany is Europe’s largest and most established transcatheter aortic valve replacement (TAVR) market, with an extensive network of experienced structural heart centers and investigators. Activating sites in this high-volume environment is anticipated to increase access to eligible patients and accelerate enrollment in the PARADIGM Trial. “Germany’s scale, clinical expertise and established TAVR infrastructure create an important opportunity to advance enrollment and extend PARADIGM’s reach across leading international TAVR markets,” said Wayne Paterson, Vice Chairman and Chief Executive Officer of Anteris. The Company continues to execute its global clinical strategy through coordinated site activation and patient enrollment across the United States and Europe. Germany’s inclusion strengthens the trial’s European presence and adds meaningful scale to the PARADIGM Trial. ENDS About the PARADIGM Trial The PARADIGM Trial is a prospective randomized controlled trial which will evaluate the safety and effectiveness of the DurAVR® Transcatheter Heart Valve compared to commercially available transcatheter aortic valve replacements (TAVRs). This head-to-head study will enrol approximately 1,000 patients in the ‘All Comers Randomized Cohort’ with 1:1 randomization of patients who will receive either the DurAVR® THV or TAVR using commercially available and approved THVs. The PARADIGM Trial will assess non-inferiority on a primary composite endpoint of all-cause mortality, all stroke and cardiovascular hospitalization at one year post procedure. For further information, please refer to ClinicalTrials.gov NCT07194265. About Anteris Anteris Technologies Global Corp. (NASDAQ: AVR, ASX: AVR) is a global healthcare company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function. Founded in Australia, with a significant presence in Minneapolis, USA, Anteris is a science-driven company with an experienced team of multidisciplinary professionals delivering restorative solutions to structural heart disease patients. Anteris’ lead product, the DurAVR® THV, was designed in collaboration with the world’s leading interventional cardiologists and cardiac surgeons to treat aortic stenosis – a potentially life-threatening condition resulting from the narrowing of the aortic valve. The balloon-expandable DurAVR® THV is the first biomimetic valve, which is shaped to mimic the performance of a healthy human aortic valve and aims to replicate normal aortic blood flow. DurAVR® THV is made using a single piece of molded ADAPT® tissue, Anteris’ patented anti-calcification tissue technology. ADAPT® tissue, which is FDA-cleared, has been used clinically for over 10 years and distributed for use in over 55,000 patients worldwide. The DurAVR® THV System is comprised of the DurAVR® valve, the ADAPT® tissue, and the balloon-expandable ComASUR® Delivery System. Forward-Looking Statements This announcement contains forward-looking statements, including statements regarding the expectation that this regulatory clearance enables patient recruitment in Germany. Forward-looking statements include all statements that are not historical facts. Forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “budget,” “target,” “aim,” “strategy,” “plan,” “guidance,” “outlook,” “may,” “should,” “could,” “will,” “would,” “will be,” “will continue,” “will likely result” and similar expressions, although not all forward-looking statements contain these identifying words. These forward-looking statements are subject to a number of risks, uncertainties, and assumptions, including those described under “Risk Factors” in Anteris’ Annual Report on Form 10-K for the fiscal period ended December 31, 2025 that was filed with the Securities and Exchange Commission and ASX. Readers are cautioned not to put undue reliance on forward-looking statements, and except as required by law, Anteris does not assume any obligation to update any of these forward-looking statements to conform these statements to actual results or revised expectations. For more information: Global Investor Relationsinvestors@anteristech.comDebbie OrmsbyAnteris Technologies Global Corp.+61 1300 550 310 | +61 7 3152 3200Investor Relations (US)mchatterjee@bplifescience.comMalini Chatterjee, Ph.D. Blueprint Life Science Group+1 917 330 4269 Website www.anteristech.comX @AnterisTechLinkedIn https://www.linkedin.com/company/anteristech



